Athletic PerformanceNAP-CAF-RECNCT07652424
Effects of Afternoon Napping, Caffeine, and Standardised Active Recovery on Evening Athletic Performance
A study testing Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol in people with Athletic Performance and Sports Performance, run by The Higher Institute of Sport and Physical Education of Sfax at 1 site in Tunisia.
Trial summary
This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes. Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- Conditions the study is for
- Athletic Performance, Sports Performance, Exercise Performance
- What is being tested?
- Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteTunisia
- Study dates
- 2 Jan 2025to 31 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy university athletes aged 18-25 years.
- Regular engagement in structured training, defined as at least 10 training sessions per week of approximately 2 h each, across team sports, judo, athletics, tennis, or swimming.
- Non-habitual napping, defined as fewer than one nap per week.
- Low habitual caffeine intake, defined as <80 mg/day, assessed using a 7-day dietary recall.
- Non-smoker and free from regular medication or recreational drug use.
- No musculoskeletal injury during the preceding month.
Show all 9Show fewer
- Good self-reported sleep quality, defined as a Pittsburgh Sleep Quality Index score <5.
- Definite morning chronotype (MEQ score 59-86) or definite evening chronotype (MEQ score 16-41).
- For female participants: self-reported regular menstrual cycles (26-32 days), no hormonal contraceptive use, and no self-reported history of menstrual disorders.
Who cannot join
- Intermediate chronotype (MEQ score 42-58).
- Habitual napping (≥1 nap per week).
- Habitual caffeine intake ≥80 mg/day.
- Smoking, regular medication use, or recreational drug use.
- Musculoskeletal injury during the preceding month.
- Pittsburgh Sleep Quality Index score ≥5.
Show all 9Show fewer
- Self-reported irregular menstrual cycles, hormonal contraceptive use, or history of menstrual disorders in female participants.
- Self-reported sleep disorder.
- Inability or unwillingness to complete all five experimental conditions.
Trial locations and contacts
1 site in 1 country.
Tunisia1 site
Higher Institute of Sport and Physical Education of Sfax (ISSEP Sfax)
Sfax, 3000
About this study
Official title: Effects of Afternoon Napping, Caffeine, and a Standardised Active Recovery Protocol on Evening Athletic Performance According to Sex and Chronotype: A Randomised Crossover Trial
This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes.
Participants completed five experimental conditions in a randomised crossover design: placebo without napping, napping with placebo, caffeine without napping, napping combined with caffeine, and napping combined with caffeine plus a standardised active recovery and nutritional protocol. The nap opportunity lasted 90 minutes and caffeine was administered at 5 mg/kg body mass.
The main outcome was repeated agility performance. Additional outcomes included sprint performance, jumping performance, reaction time, subjective sleepiness, sleep characteristics during the nap opportunity, and selected physiological measures. The study also explored whether responses differed according to sex and chronotype.
Read the detailed description
This randomised, placebo-controlled crossover study examined the isolated and combined effects of afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol on evening athletic performance.
Participants completed five experimental conditions in a counterbalanced Latin-square order, with at least 72 h between sessions:
- PLA: placebo capsule at 18:00, without a nap opportunity.
- NAP: 90-min nap opportunity from 13:00 to 14:30 plus placebo capsule at 18:00.
- CAF: caffeine ingestion at 18:00 (5 mg/kg body mass) without a nap opportunity.
- NAP+CAF: 90-min nap opportunity plus caffeine ingestion at 18:00.
- NAP+CAF+REC: 90-min nap opportunity plus caffeine ingestion at 18:00 and a standardised active recovery and nutritional protocol from 18:45 to 19:00.
The active recovery and nutritional protocol included a standardised lower-limb dynamic stretching routine followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. The protocol was identical for all participants allocated to this condition.
Participants were stratified by sex and chronotype before condition allocation. Capsule allocation was double-blinded: participants, outcome assessors, and the testing team were unaware of whether caffeine or placebo had been administered. Blinding of nap and active recovery components was not possible because of the nature of these interventions.
The primary outcome was total time during the Repeated Modified Agility Test. Secondary performance outcomes included 20-m sprint time, countermovement jump height, squat jump height, simple reaction time, choice reaction time, and subjective sleepiness. Nap sleep characteristics were assessed using portable electroencephalographic monitoring. Physiological measures included heart-rate variability, salivary cortisol, plasma brain-derived neurotrophic factor, and blood lactate.
All sessions were conducted under standardised sleep, dietary, and activity-control procedures. The study explored whether intervention responses differed by sex and chronotype.
- Being tested
- Afternoon Nap, Caffeine, Standardised Active Recovery and Nutritional Protocol, Placebo
- Keywords
- Napping, Caffeine, Recovery Protocol, Chronotype, Sex Differences, Evening Performance, Crossover Trial, Randomised Controlled Trial, Brain-Derived Neurotrophic Factor, Heart Rate Variability, Reaction Time, Agility, Jump Performance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Afternoon NapBehavioural
A 90-min afternoon nap opportunity from 13:00 to 14:30 in a quiet, dimly lit, temperature-controlled room. Sleep was monitored using a portable EEG headband. Participants were provided with earplugs and eye masks, and nap sleep characteristics, including sleep stages, were recorded.
CaffeineDietary supplement
Anhydrous caffeine (5 mg/kg body mass) was administered orally in an opaque capsule at 18:00. Placebo capsules contained microcrystalline cellulose and were matched for appearance, mass, colour, and odour. Capsule allocation was blinded to participants and outcome assessors.
Standardised Active Recovery and Nutritional ProtocolCombination product
A 15-min standardised active recovery and nutritional protocol performed from 18:45 to 19:00. It included lower-limb dynamic stretching exercises (forward/backward and lateral leg swings, walking lunges, high knees, and butt kicks; 10 repetitions per leg at a controlled pace), followed by ingestion of a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate mixed with 200 mL water.
PlaceboOther
Microcrystalline cellulose was administered orally in an opaque capsule at 18:00. Placebo capsules were matched to caffeine capsules for appearance, mass, colour, and odour.
| Study group | Role | What they receive |
|---|---|---|
| PLA | Placebo comparator | Placebo capsule (microcrystalline cellulose) at 18:00, no nap opportunity Receives: Other: Placebo |
| NAP | Experimental | 90-minute afternoon nap opportunity (13:00-14:30) with objective sleep architecture recording via portable EEG headband (Dreem 3), followed by placebo capsule (microcrystalline cellulose) at 18:00. Participants remained in a quiet, dimly lit room during the nap opportunity. Receives: Behavioral: Afternoon Nap; Other: Placebo |
| CAF | Experimental | Caffeine ingestion (5 mg/kg body mass of anhydrous caffeine) at 18:00, no nap opportunity. Participants remained in a quiet, dimly lit room during the 13:00-14:30 period. Receives: Dietary Supplement: Caffeine |
| NAP+CAF | Experimental | 90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, followed by caffeine ingestion (5 mg/kg) at 18:00. Receives: Behavioral: Afternoon Nap; Dietary Supplement: Caffeine |
| NAP+CAF+REC | Experimental | 90-min afternoon nap opportunity (13:00-14:30) with portable EEG monitoring, caffeine ingestion (5 mg/kg body mass) at 18:00, and a 15-min standardised active recovery and nutritional protocol from 18:45 to 19:00. The protocol included lower-limb dynamic stretching followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. Receives: Behavioral: Afternoon Nap; Dietary Supplement: Caffeine; Combination Product: Standardised Active Recovery and Nutritional Protocol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Repeated Modified Agility Test (RMAT) Total Time
Total time (seconds) to complete 10 maximal 20-m sprints with four changes of direction (forward sprint, left shuffle, right shuffle, backward sprint). The test was conducted on an indoor hardwood court using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start/finish line. Participants started from a standing position 0.5 m behind the first photocell. Lower values indicate better repeated agility performance. This was the primary outcome measure used for sample size calculation.
Measured: At approximately 19:35 on each of the five experimental days
Secondary outcomes (10)
Countermovement Jump (CMJ) Height
Maximum jump height (cm) calculated from flight time using the formula h = g·t²/8, where g = 9.81 m·s-². Participants started from an upright standing position, performed a rapid downward movement to approximately 90° knee flexion, and immediately jumped vertically, maintaining hands on hips throughout. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained. Measured using an optical measurement system (Optojump Next, Microgate SRL, Bolzano, Italy) with a sampling frequency of 1000 Hz. Higher values indicate better explosive lower-limb performance.
Measured: At approximately 19:20 on each of the five experimental days.
Squat Jump (SJ) Height
Maximum jump height (cm) from a static squat position with knees at approximately 90° flexion, hands on hips. Participants held the starting position for 2-3 seconds before jumping vertically without any countermovement. Three maximal attempts were performed with 2 minutes of rest between attempts; the highest jump height was retained for analysis. Calculated from flight time using h = g·t²/8. Measured using Optojump Next optical system (1000 Hz sampling frequency). Higher values indicate better explosive lower-limb performance without stretch-shortening cycle contribution.
Measured: At approximately 19:25 on each of the five experimental days.
20-m Sprint Time
Best time (seconds) of two maximal 20-m sprints from a standing start, with 3 minutes of passive recovery between sprints. Participants started 0.5 m behind the start line. Sprint time was measured using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start (0 m) and finish (20 m) lines. Lower values indicate better linear sprint performance.
Measured: At approximately 19:45 on each of the five experimental days.
Simple Reaction Time (SRT)
Mean reaction time (milliseconds) across 15 recorded trials. A green circle appeared on a black background on a 15-inch laptop screen (60 Hz refresh rate), and participants pressed the space bar as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster simple reaction time and better cognitive processing speed.
Measured: At approximately 19:15 on each of the five experimental days.
Choice Reaction Time (CRT)
Mean reaction time (milliseconds) across 15 recorded trials. Either a red circle (press the left arrow key) or a blue square (press the right arrow key) appeared randomly on a 15-inch laptop screen (60 Hz refresh rate). Participants had to identify the stimulus and press the correct key as quickly as possible. Inter-trial interval varied randomly between 1000 and 2000 ms. Measured using OpenSesame software (version 3.3). Lower values indicate faster choice reaction time and better cognitive decision-making speed.
Measured: At approximately 19:20 on each of the five experimental days.
Heart Rate Variability (RMSSD and HF Power)
Heart-rate variability was recorded during 5-min supine resting measurements with spontaneous breathing using a Polar H10 chest strap. RR intervals were analysed using Kubios HRV software after artefact correction. The main HRV variables were RMSSD (ms) and high-frequency power (0.15-0.40 Hz, normalised units).
Measured: At 12:00, 18:00, and approximately 19:45 on each of the five experimental days.
Salivary Cortisol Concentration
Salivary cortisol concentration (nmol/L) measured using Salivette cotton swabs (Sarstedt, Nümbrecht, Germany). Participants were instructed to avoid eating, drinking (except water), and brushing teeth for 30 minutes before each sample. Samples were centrifuged at 1500×g for 10 minutes at 4°C, and the supernatant was stored at -80°C until analysis. Cortisol concentration was measured in duplicate using a high-sensitivity enzyme-linked immunosorbent assay (ELISA, IBL International, Hamburg, Germany) with a detection limit of 0.05 ng/mL and intra- and inter-assay coefficients of variation < 8%. Lower values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activity.
Measured: At 12:00, 18:00, approximately 19:45, and 30 minutes after exercise on each of the five experimental days.
Plasma Brain-Derived Neurotrophic Factor (BDNF)
BDNF concentration (pg/mL) measured in venous blood samples (5 mL) drawn from an antecubital vein. Blood was collected into EDTA tubes, immediately centrifuged at 1500×g for 15 minutes at 4°C, and plasma was stored at -80°C until analysis. BDNF concentration was quantified using a commercially available ELISA kit (R\&D Systems, Minneapolis, MN, USA; catalogue number DBD00) with a detection limit of 20 pg/mL and intra- and inter-assay CVs < 6% and < 9%, respectively. Higher values indicate greater neurotrophic activity.
Measured: Measured at baseline and after completion of the evening testing battery on each experimental day.
Blood Lactate Concentration
Lactate concentration (mmol/L) measured in capillary blood samples (5 µL) collected from the fingertip using a Lactate Pro 2 analyzer (Arkray, Kyoto, Japan), which has a coefficient of variation < 3%. Higher values indicate greater metabolic perturbation and glycolytic activation during high-intensity exercise.
Measured: At 18:55, 3 minutes after the Repeated Modified Agility Test, and 3 minutes after the 20-m sprint on each of the five experimental days.
Nap Architecture (EEG)
Objective sleep parameters recorded using a validated dry-electrode portable EEG headband (Dreem 3, Paris, France) with six channels (F3, F4, C3, C4, O1, O2, referenced to linked mastoids). Sleep stages were automatically scored in 30-second epochs using the manufacturer's algorithm and visually corrected by a certified sleep technologist blinded to condition and participant. Parameters extracted: total sleep time (TST, minutes), sleep onset latency (SOL, minutes), time in N2 sleep (minutes), time in N3 slow-wave sleep (minutes), time in REM sleep (minutes), and sleep efficiency (TST/time in bed × 100, %).
Measured: During the 90-minute nap opportunity from 13:00 to 14:30 on NAP, NAP+CAF, and NAP+CAF+REC condition days only.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start2 Jan 2025
- Primary completion31 May 2025
- Study completion31 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Athletic PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomised, counterbalanced crossover design with 5 experimental conditions. Each participant completes all conditions in a different order determined by Latin square randomisation. Washout period between conditions: at least 72 hours.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Higher Institute of Sport and Physical Education of Sfax
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kais Elabed, The Higher Institute of Sport and Physical Education of Sfax
- Investigators
- Kais El Abed, Phd, Principal investigator, University of Sfax, Tunisia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07652424
- Sponsor's protocol ID
- ISSEPS-NAP-CAF-REC-2025
- Acronym
- NAP-CAF-REC
- Status last verified
- Jun 2026
- First submitted
- 10 Jun 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymised individual participant data (IPD) will be shared for all 60 participants across all five experimental conditions (300 experimental sessions). Data will include: demographic characteristics, anthropometric measures, chronotype classification (MEQ scores), sleep quality (PSQI scores), nap architecture (EEG-derived sleep stages), physical performance outcomes (RMAT, CMJ, SJ, 20-m sprint), cognitive performance outcomes (SRT, CRT), subjective sleepiness (ESS, KSS), and physiological biomarkers (HRV-RMSSD, HF power, salivary cortisol, plasma BDNF, blood lactate). All data will be fully anonymised using coded identifiers (S01-S60), with the identification key stored separately on encrypted institutional servers.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Afternoon Napping, Caffeine, and a Standardised Active Recovery Protocol on Evening Athletic Performance According to Sex and Chronotype: A Randomised Crossover Trial
- ClinicalTrials.gov ID
- NCT07652424
- Acronym / sponsor ID
- NAP-CAF-REC / ISSEPS-NAP-CAF-REC-2025
- Keywords
- Napping, Caffeine, Recovery Protocol, Chronotype, Sex Differences, Evening Performance, Crossover Trial, Randomised Controlled Trial
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- The Higher Institute of Sport and Physical Education of SfaxUniversity, hospital or other
- Study start
- 2 Jan 2025 (actual)
- Primary completion
- 31 May 2025 (actual)
- Study completion
- 31 May 2025 (actual)
- First posted
- 17 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated whether afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol could influence evening physical and cognitive performance in healthy university athletes.
Participants completed five experimental conditions in a randomised crossover design: placebo without napping, napping with placebo, caffeine without napping, napping combined with caffeine, and napping combined with caffeine plus a standardised active recovery and nutritional protocol. The nap opportunity lasted 90 minutes and caffeine was administered at 5 mg/kg body mass.
The main outcome was repeated agility performance. Additional outcomes included sprint performance, jumping performance, reaction time, subjective sleepiness, sleep characteristics during the nap opportunity, and selected physiological measures. The study also explored whether responses differed according to sex and chronotype.
Detailed description
This randomised, placebo-controlled crossover study examined the isolated and combined effects of afternoon napping, caffeine ingestion, and a standardised active recovery and nutritional protocol on evening athletic performance.
Participants completed five experimental conditions in a counterbalanced Latin-square order, with at least 72 h between sessions:
- PLA: placebo capsule at 18:00, without a nap opportunity.
- NAP: 90-min nap opportunity from 13:00 to 14:30 plus placebo capsule at 18:00.
- CAF: caffeine ingestion at 18:00 (5 mg/kg body mass) without a nap opportunity.
- NAP+CAF: 90-min nap opportunity plus caffeine ingestion at 18:00.
- NAP+CAF+REC: 90-min nap opportunity plus caffeine ingestion at 18:00 and a standardised active recovery and nutritional protocol from 18:45 to 19:00.
The active recovery and nutritional protocol included a standardised lower-limb dynamic stretching routine followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. The protocol was identical for all participants allocated to this condition.
Participants were stratified by sex and chronotype before condition allocation. Capsule allocation was double-blinded: participants, outcome assessors, and the testing team were unaware of whether caffeine or placebo had been administered. Blinding of nap and active recovery components was not possible because of the nature of these interventions.
The primary outcome was total time during the Repeated Modified Agility Test. Secondary performance outcomes included 20-m sprint time, countermovement jump height, squat jump height, simple reaction time, choice reaction time, and subjective sleepiness. Nap sleep characteristics were assessed using portable electroencephalographic monitoring. Physiological measures included heart-rate variability, salivary cortisol, plasma brain-derived neurotrophic factor, and blood lactate.
All sessions were conducted under standardised sleep, dietary, and activity-control procedures. The study explored whether intervention responses differed by sex and chronotype.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 5
- Model description
- Randomised, counterbalanced crossover design with 5 experimental conditions. Each participant completes all conditions in a different order determined by Latin square randomisation. Washout period between conditions: at least 72 hours.
| Arm | Type | Receives |
|---|---|---|
| PLA | Placebo comparator | Other: PlaceboPlacebo capsule (microcrystalline cellulose) at 18:00, no nap opportunity |
| NAP | Experimental | Behavioral: Afternoon Nap, Other: Placebo90-minute afternoon nap opportunity (13:00-14:30) with objective sleep architecture recording via portable EEG headband (Dreem 3), followed by placebo capsule (microcrystalline cellulose) at 18:00. Participants remained in a quiet, dimly lit room during the nap opportunity. |
| CAF | Experimental | Dietary Supplement: CaffeineCaffeine ingestion (5 mg/kg body mass of anhydrous caffeine) at 18:00, no nap opportunity. Participants remained in a quiet, dimly lit room during the 13:00-14:30 period. |
| NAP+CAF | Experimental | Behavioral: Afternoon Nap, Dietary Supplement: Caffeine90-minute afternoon nap opportunity (13:00-14:30) with EEG recording, followed by caffeine ingestion (5 mg/kg) at 18:00. |
| NAP+CAF+REC | Experimental | Behavioral: Afternoon Nap, Dietary Supplement: Caffeine, Combination Product: Standardised Active Recovery and Nutritional Protocol90-min afternoon nap opportunity (13:00-14:30) with portable EEG monitoring, caffeine ingestion (5 mg/kg body mass) at 18:00, and a 15-min standardised active recovery and nutritional protocol from 18:45 to 19:00. The protocol included lower-limb dynamic stretching followed by a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate. |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Healthy university athletes aged 18-25 years.
- Regular engagement in structured training, defined as at least 10 training sessions per week of approximately 2 h each, across team sports, judo, athletics, tennis, or swimming.
- Non-habitual napping, defined as fewer than one nap per week.
- Low habitual caffeine intake, defined as <80 mg/day, assessed using a 7-day dietary recall.
- Non-smoker and free from regular medication or recreational drug use.
Key exclusion criteria (9 listed)
- Intermediate chronotype (MEQ score 42-58).
- Habitual napping (≥1 nap per week).
- Habitual caffeine intake ≥80 mg/day.
- Smoking, regular medication use, or recreational drug use.
- Musculoskeletal injury during the preceding month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Afternoon NapA 90-min afternoon nap opportunity from 13:00 to 14:30 in a quiet, dimly lit, temperature-controlled room. Sleep was monitored using a portable EEG headband. Participants were provided with earplugs and eye masks, and nap sleep characteristics, including sleep stages, were recorded. | Behavioural | NAP, NAP+CAF, NAP+CAF+REC |
| CaffeineAnhydrous caffeine (5 mg/kg body mass) was administered orally in an opaque capsule at 18:00. Placebo capsules contained microcrystalline cellulose and were matched for appearance, mass, colour, and odour. Capsule allocation was blinded to participants and outcome assessors. | Dietary supplement | CAF, NAP+CAF, NAP+CAF+REC |
| Standardised Active Recovery and Nutritional ProtocolA 15-min standardised active recovery and nutritional protocol performed from 18:45 to 19:00. It included lower-limb dynamic stretching exercises (forward/backward and lateral leg swings, walking lunges, high knees, and butt kicks; 10 repetitions per leg at a controlled pace), followed by ingestion of a carbohydrate-protein snack containing 20 g maltodextrin and 10 g whey isolate mixed with 200 mL water. | Combination product | NAP+CAF+REC |
| PlaceboMicrocrystalline cellulose was administered orally in an opaque capsule at 18:00. Placebo capsules were matched to caffeine capsules for appearance, mass, colour, and odour. | Other | NAP, PLA |
Primary outcome
Repeated Modified Agility Test (RMAT) Total Time
Time frame: At approximately 19:35 on each of the five experimental days
Total time (seconds) to complete 10 maximal 20-m sprints with four changes of direction (forward sprint, left shuffle, right shuffle, backward sprint). The test was conducted on an indoor hardwood court using dual-beam photocells (Brower Timing Systems, Salt Lake City, UT, USA) placed at the start/finish line. Participants started from a standing position 0.5 m behind the first photocell. Lower values indicate better repeated agility performance. This was the primary outcome measure used for sample size calculation.
10 secondary outcomes
Countermovement Jump (CMJ) Height
Time frame: At approximately 19:20 on each of the five experimental days.
Squat Jump (SJ) Height
Time frame: At approximately 19:25 on each of the five experimental days.
20-m Sprint Time
Time frame: At approximately 19:45 on each of the five experimental days.
Simple Reaction Time (SRT)
Time frame: At approximately 19:15 on each of the five experimental days.
Choice Reaction Time (CRT)
Time frame: At approximately 19:20 on each of the five experimental days.
Heart Rate Variability (RMSSD and HF Power)
Time frame: At 12:00, 18:00, and approximately 19:45 on each of the five experimental days.
Salivary Cortisol Concentration
Time frame: At 12:00, 18:00, approximately 19:45, and 30 minutes after exercise on each of the five experimental days.
Plasma Brain-Derived Neurotrophic Factor (BDNF)
Time frame: Measured at baseline and after completion of the evening testing battery on each experimental day.
Blood Lactate Concentration
Time frame: At 18:55, 3 minutes after the Repeated Modified Agility Test, and 3 minutes after the 20-m sprint on each of the five experimental days.
Nap Architecture (EEG)
Time frame: During the 90-minute nap opportunity from 13:00 to 14:30 on NAP, NAP+CAF, and NAP+CAF+REC condition days only.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Open Science Framework - Data RepositoryLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymised individual participant data (IPD) will be shared for all 60 participants across all five experimental conditions (300 experimental sessions). Data will include: demographic characteristics, anthropometric measures, chronotype classification (MEQ scores), sleep quality (PSQI scores), nap architecture (EEG-derived sleep stages), physical performance outcomes (RMAT, CMJ, SJ, 20-m sprint), cognitive performance outcomes (SRT, CRT), subjective sleepiness (ESS, KSS), and physiological biomarkers (HRV-RMSSD, HF power, salivary cortisol, plasma BDNF, blood lactate). All data will be fully anonymised using coded identifiers (S01-S60), with the identification key stored separately on encrypted institutional servers.
Related trials for Athletic Performance
Recruiting
Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
Athletic Performance, Hyperbaric Oxygenation
Not yet recruiting
Core Strength Training, Anthropometry, and Postural Control in Youth Optimist Sailors
Postural Control, Athletic Performance
Recruiting
Effects of Scapular Training on Adolescent Boxers
Sports Physical Therapy
Active, not recruiting
Effects of Blood Flow Restriction Training on Physical Function, Muscle Adaptations, and Performance in Roller Skaters
Athletic Performance Enhancement
Recruiting
UCLA Magnesium Formulation Athlete Study
Athletic Performance, Recovery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kais El Abed, Phd principal investigator
University of Sfax, Tunisia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Afternoon Nap, Caffeine and Standardised Active Recovery and Nutritional Protocol in people with Athletic Performance and Sports Performance, run by The Higher Institute of Sport and Physical Education of Sfax at 1 site in Tunisia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Repeated Modified Agility Test (RMAT) Total Time (time frame: At approximately 19:35 on each of the five experimental days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.